Abstracts tagged "risk assessment"

Abstract Number: 1526 • ACR Convergence 2022
Developing a Screening Tool for the Detection of Interstitial Lung Disease in Systemic Sclerosis: The ILD-RISC Risk Score
cosimo bruni¹, Lorenzo Tofani¹, Håvard Fretheim², Sophie Liem³, Arthiha Velauthapillai⁴, Hilde Jenssen Bjørkekjær⁵, Imon Barua², Ilaria Galetti⁶, Alexandru Garaiman⁷, Mike Becker⁷, Anna-Maria Hoffmann-Vold², Jeska de Vries-Bouwstra⁸, Madelon Vonk⁹, Jörg Distler¹⁰, Marco Matucci-Cerinic¹ and Oliver Distler⁷, ¹University of Florence, Florence, Italy, ²Oslo University Hospital, Oslo, Norway, ³LUMC, Leiden, Netherlands, ⁴Radboud University Medical Center, Nijmegen, Nijmegen, Netherlands, ⁵Department of Rheumatology, Hospital of Southern Norway, Kristiansand, Norway, Kristiansand, Norway, ⁶Gruppo Italiano Lotta alla Sclerodermia (GILS), Milano, Italy, ⁷Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ⁸Leiden University Medical Center, Leiden, Netherlands, ⁹Department of Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, ¹⁰Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany
Background/Purpose: High resolution computed tomography (HRCT) is the gold standard for the diagnosis of systemic sclerosis associated interstitial lung disease (SSc-ILD). Although there is agreement…
Abstract Number: 0911 • ACR Convergence 2022
Peer Coach Intervention to Improve Primary Cardiovascular Disease Screening for Patients with Rheumatoid Arthritis
Iris Navarro-Millan¹, Mackenzie Brown², Yuliana Domínguez Páez³, Geyanne Lui⁴, Joan Weiner¹, Shelley fritz¹, Tien Sydnor-Campbell⁵, Aberdeen Allen⁶, Assem Jabri¹, Shilpa Venkatachalam⁷, Kelly Gavigan⁸, William Benjamin Nowell⁹, Jeffrey Curtis¹⁰, Liana Fraenkel¹¹ and Monika Safford¹, ¹Weill Cornell Medicine, New York, NY, ²Weill Cornell Medicine, Brooklyn, NY, ³Weill Cornell Medicine, Bronx, NY, ⁴Albert Einstein College of Medicine, New York, NY, ⁵Weill Cornell Medicine, Philedelphia, ⁶Weill Cornell Medicine, Parlin, ⁷Global Healthy Living Foundation, New York, NY, ⁸Global Healthy Living Foundation, Upper Nyack, NY, ⁹Global Healthy Living Foundation, Nyack, NY, ¹⁰University of Alabama at Birmingham, Hoover, AL, ¹¹Berkshire Medical Center, Lenox, MA
Background/Purpose: Only 37% of patients with rheumatoid arthritis (RA) receive screening for cardiovascular disease (CVD) despite their high risk. To improve CVD prevention, we designed…
Abstract Number: 1612 • ACR Convergence 2022
Prediction of Psoriatic Arthritis Tool (PRESTO): Development and Performance of a New Scoring System for Psoriatic Arthritis Risk
Lihi Eder¹, Ker-Ai Lee², Vinod Chandran³, Jessica Widdifield⁴, Aaron Drucker⁴, Christopher Ritchlin⁵, Cheryl F Rosen⁴, Richard Cook² and Dafna Gladman⁶, ¹Women’s College Research Institute, Department of Medicine, University of Toronto, Toronto, ON, Canada, ²University of Waterloo, Waterloo, ON, Canada, ³Departments of Medicine and Laboratory Medicine and Pathobiology, University of Toronto/ Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada, ⁵Allergy, Immunology and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, ⁶Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada
Background/Purpose: A simple, scalable tool that identifies psoriasis patients at high risk for developing PsA could improve early detection and facilitate early intervention. Our overall…
Abstract Number: 0941 • ACR Convergence 2022
Surveying Adolescents with Rheumatic Disease for At-Risk Behavior
Kristina Ciaglia¹, Chetna Godiwala², Chan-hee Jo², Tracey Wright³, Lynnette Walters² and Lorien Nassi¹, ¹University of Texas Southwestern, Dallas, TX, ²Scottish Rite Hospital for Children, Dallas, TX, ³UT Southwestern, Plano, TX
Background/Purpose: Adolescents with rheumatic disease are often prescribed teratogenic medications, however few rheumatologists screen patients for sexual activity and provide referrals or contraceptive education due…
Abstract Number: 1648 • ACR Convergence 2022
Risk of Vascular Events Under the Treatments with Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis: An Analysis Using Japanese Health Insurance Database
Eiichi Tanaka¹, Ryoko Sakai², Eisuke Inoue³ and Masayoshi Harigai¹, ¹Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan, ²Meiji Pharmaceutical University, Tokyo, Japan, ³Research Administration Center, Showa University, Shinagawa-ku, Japan
Background/Purpose: Janus kinase inhibitors (JAKIs) have shown positive therapeutic impacts on treatments for rheumatoid arthritis (RA), whereas, concerns have been raised about the risk of…
Abstract Number: 0993 • ACR Convergence 2022
SARS-CoV-2 Vaccine Side Effects and Infections in SLE
Laura Yan¹, Arielle Mendel², Evelyne Vinet², Fares Kalache³, Jennifer Lee¹, Popi Panaritis² and Sasha Bernatsky¹, ¹Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ²McGill University Health Centre, Montréal, QC, Canada, ³McGill University Health Center, Montréal, QC, Canada
Background/Purpose: SLE patients are an especially vulnerable population in the face of the COVID pandemic due to their dysregulated endogenous immune system, further downregulated by…
Abstract Number: 1984 • ACR Convergence 2022
Malignancies Risk in Rheumatoid Arthritis Patients Treated with Tofacitinib or TNF Inhibitors, a National Study: RELATION Study
jacques-eric gottenberg¹, Nadir Mammar², Meriem Kessouri², Jeremie RUDANT², nada Assi³, Fanny raguideau³ and julien kirchgesner⁴, ¹Strasbourg University Hospital, Strasbourg, France, ²Pfizer, Paris, France, ³HEVA, Lyon, France, ⁴AP-HP, Paris, France
Background/Purpose: Patients with IMID, and notably patients with rheumatoid arthritis RA, are at increased risk of cancer compared with the general population. It is hence…
Abstract Number: 1047 • ACR Convergence 2022
A Novel Prediction Tool for Progression of Systemic Sclerosis-Interstitial Lung Disease Despite Treatment with Immunosuppression
Elizabeth Volkmann¹, Holly Wilhalme¹, Grace Kim¹, Jonathan Goldin¹, Shervin Assassi², Masataka Kuwana³, Donald Tashkin¹ and Michael roth¹, ¹University of California Los Angeles, Los Angeles, CA, ²McGovern Medical School, University of Texas, Houston, TX, ³Nippon Medical School Graduate School of Medicine, Tokyo, Japan
Background/Purpose: Systemic sclerosis-interstitial lung disease (SSc-ILD) is the leading cause of SSc-related death. While some patients respond favorably to treatment with immunosuppression, a subset of…
Abstract Number: 2268 • ACR Convergence 2022
Recurrent Thrombosis Risk in Non-anticoagulated Antiphospholipid Syndrome Patients: A Prospective Case-Control Study from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Cecile Yelnik¹, Zeynep Belce Erton², Elodie Drumez³, Dachi Cheildze², Danieli Castro Oliveira de Andrade⁴, Ann E Clarke⁵, Maria G. Tektonidou⁶, Vittorio Pengo⁷, Savino Sciascia⁸, Amaia Ugarte⁹, H Michael Belmont¹⁰, Mª Angeles Aguirre¹¹, Paul fortin¹², maria gerosa¹³, Flavio Victor Signorelli¹⁴, Tatsuya Atsumi¹⁵, Zhouli Zhang¹⁶, Hannah Cohen¹⁷, D. Ware Branch¹⁸, Denis Wahl¹⁹, Laura Andreoli²⁰, Esther Rodriguez Almaraz²¹, Michelle Petri²², Ricard Cervera²³, Yu Zuo²⁴, Bahar Artim-Esen²⁵, Guillermo Pons-Estel²⁶, Rohan Willis²⁷, Maria Laura Bertolaccini²⁸, Robert Roubey²⁹, Doruk Erkan² and on behalf of APS ACTION On Behalf Of APS ACTION², ¹Lille University, Lille, France, ²Hospital for Special Surgery, New York, NY, ³Université de Lille, Lille, France, ⁴Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ⁵University of Calgary, Division of Rheumatology, Cumming School of Medicine, Calgary, AB, Canada, ⁶National and Kapodistrian University of Athens, Athens, Greece, ⁷Padova University Hospital, Padova, Italy, ⁸University of Turin, Torino, Italy, ⁹BioCruces Bizkaia Health Research Institute, Barakaldo, Spain, ¹⁰NYU School of Medicine, New York, NY, ¹¹Maimonides Institute for Biomedical Research of Córdoba, Cordoba, Spain, ¹²CHU de Québec, Pavillon CHUL, Québec, Canada, ¹³University of Milan, Milano, Italy, ¹⁴Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil, ¹⁵Hokkaido University, Sapporo, Japan, ¹⁶Peking University First Hospital, Beijing, China, ¹⁷University College London, London, United Kingdom, ¹⁸University of Utah, Salt Lake City, UT, ¹⁹Université de Nancy, Nancy, France, ²⁰Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Brescia, Italy, ²¹Hospital Universitario 12 de Octubre, Madrid, Spain, ²²Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ²³Hospital Clínic de Barcelona, Barcelona, Spain, ²⁴University of Michigan, Ann Arbor, MI, ²⁵Istanbul University, Istanbul, Turkey, ²⁶CREAR, Rosario, Argentina, ²⁷University of Texas Medical Branch, Galveston, TX, ²⁸King's College London, London, United Kingdom, ²⁹University of North Carolina, Chapel Hill, NC
Background/Purpose: Long-term anticoagulation is the standard of care for antiphospholipid syndrome (APS) patients with macrovascular thrombosis. However, in daily practice, long-term anticoagulation may not be…
Abstract Number: 1049 • ACR Convergence 2022
Risk Stratification of Patients with Systemic Sclerosis-associated Pulmonary Arterial Hypertension in EUSTAR Using the Current and New Proposed Criteria
Hilde Jenssen Bjørkekjær¹, cosimo bruni², PATRICIA E CARREIRA³, Paolo Airò⁴, CARMEN PILAR SIMEON⁵, Marie-Elise Truchetet⁶, Alessandro Giollo⁷, Alexandra Balbir-Gurman⁸, Mickaël MARTIN⁹, Chris Denton¹⁰, Armando Gabrielli¹¹, Håvard Fretheim¹², Imon Barua¹², Helle Bitter¹³, Øyvind Midtvedt¹², Kaspar Broch¹⁴, Arne Andreassen¹², Yoshiya Tanaka¹⁵, Gabriela Riemekasten¹⁶, Ulf Müller-Ladner¹⁷, Marco Matucci-Cerinic², Ivan Castellvi¹⁸, Elise Siegert¹⁹, Eric Hachulla²⁰, Oliver Distler²¹ and Anna-Maria Hoffmann-Vold¹², ¹Department of Rheumatology, Hospital of Southern Norway, Kristiansand, Norway, Kristiansand, Norway, ²University of Florence, Florence, Italy, ³HOSPITAL 12 DE OCTUBRE, Madrid, Spain, ⁴Rheumatology and Clinical Immunology Unit, ASST Spedali Civili, Brescia, Italy, ⁵Hospital Vall D'Hebron, Barcelona, Spain, ⁶CHU de Bordeaux, Bordeaux, France, ⁷Rheumatology Section, Department of Medicine, University of Verona, Italy, Verona, Italy, ⁸Rheumatology Institute, Rambam Health Care Campus, Haifa, Israel, ⁹Poitiers's Universatory Hospital, Department of Internal Medicine, Poitiers, France, Mignaloux-Beauvoir, France, ¹⁰University College London, London, United Kingdom, ¹¹Università Politecnica delle Marche, Ancona, Italy, ¹²Oslo University Hospital, Oslo, Norway, ¹³Sorlandet sykehus, Kristiansand, Norway, ¹⁴Oslo University Hospital, Rikshospitalet, Department of Cardiology, Oslo, Norway, Oslo, Norway, ¹⁵University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, ¹⁶University Clinic Schleswit-Holstein (UKSH), Luebeck, Germany, ¹⁷JLU Campus KK, Bad Nauheim, Germany, ¹⁸Hospital Universitari de la Santa Creu i Sant Pau, Vilafranca del Pened, Spain, ¹⁹Charité Hospital, Berlin, Germany, ²⁰University of Lille, LILLE, France, ²¹Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland
Background/Purpose: Pulmonary arterial hypertension (PAH) is a major clinical challenge in systemic sclerosis (SSc). A new definition for precapillary PH is proposed. Risk stratification is…
Abstract Number: 1249 • ACR Convergence 2022
Short-term Variations in Subchondral Tibial Bone Texture of Conventional X-Rays Predicts Knee Osteoarthritis Progression
Ahmad Almhdie-Imjabbar¹, Hechmi TOUMI², Zineb ZERZOUF³ and Eric LESPESSAILLES⁴, ¹University of Orleans / CHR Orleans, France, Orleans, Centre, France, ²Regional hospital centre of Orleans, France, Orleans, France, ³University of Tours, Tours, France, ⁴Regional hospital centre of Orleans, France, ORLEANS, Centre, France
Background/Purpose: Early detection and assessment of Knee Osteoarthritis (KOA) prognostic factors are crucial for developing management and treatments that aim at prevention of irreversible damage…
Abstract Number: L16 • ACR Convergence 2021
Breakthrough COVID-19 Infections Post-vaccination Among Immunocompromised Patients with Autoimmune or Inflammatory Rheumatic Diseases: A Retrospective Cohort Analysis from a U.S. Nationally-sampled Electronic Medical Record Data Repository
Jasvinder Singh¹, Namrata Singh², Alfred Anzalone³, Amy Olex⁴, Jing Sun⁵, Vithal Madhira⁶ and Rena Patel⁷, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Washington, Bellevue, WA, ³University of Nebraska, Omaha, NE, ⁴Virginia Commonwealth University, Richmond, VA, ⁵Johns Hopkins University, Baltimore, MD, ⁶Palila Software, Reno, NV, ⁷Unviersity of Washington, Seattle, WA
Background/Purpose: National U.S. data on breakthrough COVID-19 infection in people with autoimmune or inflammatory rheumatic diseases (AIRD) are limited. Our objective was to assess whether breakthrough COVID-19 infections were increased post-COVID-19-vaccination…
Abstract Number: 0285 • ACR Convergence 2021
Risk of Cardiovascular Disease in Newly Diagnosed Rheumatoid Arthritis: A Current Risk Assessment
Reinder Raadsen¹, Romy Hansildaar¹, Maaike Heslinga², Arno van Kuijk¹ and Michael Nurmohamed³, ¹Reade, Amsterdam, Netherlands, ²Amsterdam University Medical Center, location VUmc, Amsterdam, Netherlands, ³Reade and Amsterdam University Medical Center, location VUmc, Amsterdam, Netherlands
Background/Purpose: Patients with rheumatoid arthritis (RA) are known to have an increased risk of developing, mainly ischemic cardiovascular diseases (CVD). This is partly explained by…
Abstract Number: 0324 • ACR Convergence 2021
Machine Learning: Identifying Lupus Nephritis Within Systemic Lupus Erythematosus in the Real World
Bruno Teixeira, David Bell, Tim Holbrook and Ben Hoskin, Adelphi Real World, Bollington, United Kingdom
Background/Purpose: Around 40-70% of patients with systemic lupus erythematosus (SLE) develop lupus nephritis (LN). LN is often underdiagnosed and early diagnosis is crucial for reducing…
Abstract Number: 0388 • ACR Convergence 2021
Prediction Tool for Damage Accrual Trajectory in Incident Systemic Sclerosis
Ariane Barbacki¹, Ada Man², Mianbo Wang³, Dylan Johnson⁴, Yuqing Zhang⁵, Mandana Nikpour⁶ and Murray Baron⁷, ¹McGill University, Montral, Montréal, QC, Canada, ²University of Manitoba, Winnipeg, MB, Canada, ³Lady Davis institute for Medical Research, Montréal, QC, Canada, ⁴University of Alberta, Edmonton, AB, Canada, ⁵Massachusetts General Hospital, Quincy, MA, ⁶University of Melbourne at St Vincent's Hospital, Melbourne, Australia, ⁷Jewish General Hospital, Montréal, QC, Canada
Background/Purpose: Systemic sclerosis (SSc) is a systemic autoimmune disease associated with the accrual of organ damage over time, which can be measured using the Scleroderma…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].